Following the successful launch of the KY1 clinical trial, the first patient was quickly enrolled and received their first dose on October 25, 2024. The patient has shown good tolerance thus far. KY1 is the world's first small-molecule targeted drug against the RNA helicase DHX33, designed to offer new treatment options for cancer patients who have not responded to standard therapies. This trial represents a significant milestone in the clinical application of the drug, and further evaluations of its safety and efficacy will continue.